In parallel, the advent of novel HF therapies, particularly sodium-glucose cotransporter 2 inhibitors (SGLT2i) and the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan, has markedly improved clinical outcomes across HF phenotypes. This evidence concerns the gene SLC5A2 and hydrops fetalis.